Yan Leyfman: Safer CAR T cell therapy for solid tumors
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“Researchers at Memorial Sloan Kettering Cancer Center, led by Dr. David Scheinberg, have engineered a safer CAR T cell therapy for solid tumors! Traditional CAR T cells targeting GD2 caused fatal neurotoxicity by attacking normal brain tissue.
To overcome this, the team designed MEAT (Microenvironment Actuated T) cells, which activate only in the tumor environment by responding to P-selectin. This innovation prevents brain toxicity while maintaining antitumor effects, offering a promising path to expand CAR T therapy for solid tumors.”
“Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity”
Authors: Kristen C. Vogt, Qianqian Lin, James E. Han, Amy Laflin, Hendryck A. Gellineau, Daniel A. Heller, David A. Scheinberg
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023